Product news

Share this article:
Amgen said the European Commission has granted a conditional marketing authorization for Vectibix (panitumumab) as monotherapy for the treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer with non-mutated (wild-type) KRAS genes after failure of standard chemotherapy regimens.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.